A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder

Munizza, Carmine; Olivieri, L.; Loreto, Giorgio Di; Dionisio, Paolo

doi:10.1185/030079906x121039

Cited by 41 publications

(26 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are consistent with a large amount of evidence demonstrating the efficacy of other trazodone formulations in the treatment of MDD [6,7,8,9]. The HAMD-17 total score of the prolonged-release trazodone group at baseline in our study was consistent with that reported from two similar European multicenters, double-blind, randomized trials [7,8], but the changes in HAMD-17 total score from baseline to the end of the study as well as response and remission rates (-11.07, 59.6, and 35.5%, respectively) were lower than in the other two studies (-14.6, 87.3, and 69.1%, respectively; -12.9, 74.2, and 59.7%, respectively). Maybe this is due to the average daily dose of prolonged-release trazodone (273.11 mg) in our study that was below the average daily dose of the other two studies (305 and 297 mg).…”

Section: Discussionsupporting

confidence: 79%

“…Prolonged-release trazodone was well tolerated: most AEs were mild to moderate in intensity and led to few discontinuations, and this corresponds with other studies [7,8,9]. Eleven (6.0%) patients in the prolonged-release trazodone group and 4 (2.2%) patients in the placebo group discontinued due to AEs such as somnolence and dizziness.…”

Section: Discussionsupporting

confidence: 58%

“…Besides, sleep disturbances were significantly less evident for patients who received trazodone treatment compared with sertraline and paroxetine [7,8]. It is well known that a low dose (25-100 mg) of trazodone has therapeutic activity as a hypnotic [11].…”

Section: Discussionmentioning

confidence: 99%

“…Eleven (6.0%) patients in the prolonged-release trazodone group and 4 (2.2%) patients in the placebo group discontinued due to AEs such as somnolence and dizziness. In other studies, patients treated with prolonged-release trazodone discontinued due to AEs such as dizziness, sedation, and somnolence [9] and anxiety, insomnia, and tremor [8]. …”

Section: Discussionmentioning

confidence: 99%

“…In another study of prolonged-release trazodone at 150-450 mg/day (n = 62) versus sertraline at 20-40 mg/day (n = 60), trazodone and sertraline were equally effective in reducing depressive symptoms and in promoting remission, and had similar onset times. However, sleep disturbances were significantly less evident for patients receiving trazodone at the study end point [8]. …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Efficacy and Safety of Prolonged-Release Trazodone in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Flexible-Dose Trial

Zhang

Xie

et al. 2014

Pharmacology

View full text Add to dashboard Cite

Objective: To investigate the efficacy, safety, and clinical benefit of prolonged-release trazodone (Trittico) in the treatment of major depressive disorder (MDD). Methods: In this study, 363 Chinese patients with MDD were randomized 1:1 to receive either prolonged-release trazodone (150-450 mg) or placebo treatment for 6 weeks. The primary efficacy measurement was the change of the 17-item Hamilton Depression Rating Scale (HAMD-17) total score from baseline to the end of the study. The secondary efficacy measurements were the response and remission rates, the Clinical Global Impression - Improvement of Illness (CGI-I) score at the end of the study, and the change of the HAMD-14 total score and quality of sleep [evaluated by the Pittsburgh Sleep Quality Index (PSQI) scale] during the study period. Results: The mean maximum daily dose was 273.11 mg for the trazodone group and 290.92 mg for the placebo group. At the end of the study, there was a significant difference between the two groups in the HAMD-17 change score (trazodone vs. placebo: -11.07 vs. -8.29, p < 0.001). Trazodone showed advantages at 1 week of treatment, and the effect lasted until the end of the study (week 6). The response and remission rates of the trazodone group were significantly higher than those in the placebo group (response rate: 59.6 vs. 37.2%, p < 0.001; remission rate: 35.5 vs. 22.2%, p = 0.005). The majority of the adverse reactions of trazodone were mild to moderate, and the most frequent adverse reactions (≥5%) were dizziness, dry mouth, somnolence, and nausea. Conclusions: Prolonged-release trazodone was more effective than placebo in MDD and was well tolerated. i 2014 S. Karger AG, Basel

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionsupporting

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and Safety of Prolonged-Release Trazodone in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Flexible-Dose Trial

Zhang

Xie

et al. 2014

Pharmacology

View full text Add to dashboard Cite

show abstract

Sertraline versus other antidepressive agents for depression

Cipriani

Ferla

Furukawa

et al. 2009

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Sertraline versus other antidepressive agents for depression

Cipriani

Ferla

Furukawa

et al. 2010

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background-The National Institute for Health and Clinical Excellence clinical practice guideline on the treatment of depressive disorder recommended that selective serotonin reuptake inhibitors should be the first-line option when drug therapy is indicated for a depressive episode. Preliminary evidence suggested that sertraline might be slightly superior in terms of effectiveness. Objectives-To assess the evidence for the efficacy, acceptability and tolerability of sertraline in comparison with tricyclics (TCAs), heterocyclics, other SSRIs and newer agents in the acutephase treatment of major depression.

show abstract

A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder

Cited by 41 publications

References 17 publications

Efficacy and Safety of Prolonged-Release Trazodone in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Flexible-Dose Trial

Efficacy and Safety of Prolonged-Release Trazodone in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Flexible-Dose Trial

Sertraline versus other antidepressive agents for depression

Sertraline versus other antidepressive agents for depression

Contact Info

Product

Resources

About